Headspace vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Headspace is a mindfulness and mental health app offering guided meditation, sleep content, and enterprise employee wellbeing programs to over 70 million users.
About
Headspace is a mental wellness company founded in 2010 by Andy Puddicombe and Rich Pierson that has grown into one of the most widely used mindfulness and meditation apps globally. The platform offers guided meditation sessions, sleep content, stress reduction exercises, and mental fitness programs for both individual consumers and enterprise employees through its Headspace for Work product. Headspace merged with Ginger, a mental health coaching and therapy platform, in 2021 to form Headspace Health, expanding from mindfulness content into clinical mental health services. The combined platform provides a continuum from self-guided wellness content through human-delivered coaching and therapy, serving both consumers and employers who want comprehensive mental health benefits. Headspace for Work serves over 4,000 employer customers providing evidence-backed mental wellness programs to millions of employees globally. The company has published research demonstrating measurable improvements in stress, burnout, and resilience from Headspace use. Following the merger, Headspace has integrated its consumer brand recognition with Ginger's clinical platform to serve the full spectrum of mental health needs.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.